 Genprex, Inc. NASDAQ:GNPX revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some patent applications and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The Austin, Texas-based clinical-stage gene therapy company focused on developing novel therapies for patients with cancer and diabetes, noted that the preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the companys existing diabetes technology. 